Alimera Sciences, Inc. (NASDAQ:ALIM) Short Interest Update

Alimera Sciences, Inc. (NASDAQ:ALIM) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 94,700 shares, a decrease of 25.4% from the May 31st total of 127,000 shares. Based on an average trading volume of 248,800 shares, the short-interest ratio is presently 0.4 days.

Institutional Trading of Alimera Sciences

Several large investors have recently added to or reduced their stakes in ALIM. Fifth Lane Capital LP acquired a new position in shares of Alimera Sciences in the first quarter worth about $83,000. Hillsdale Investment Management Inc. bought a new position in shares of Alimera Sciences in the 1st quarter worth about $169,000. Ancora Advisors LLC bought a new position in Alimera Sciences in the first quarter worth about $915,000. Worth Venture Partners LLC acquired a new position in Alimera Sciences during the 3rd quarter valued at approximately $1,840,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after acquiring an additional 396,506 shares during the period. 99.83% of the stock is currently owned by institutional investors and hedge funds.

Alimera Sciences Stock Up 0.5 %

ALIM stock opened at $5.56 on Monday. Alimera Sciences has a one year low of $2.60 and a one year high of $5.65. The company has a 50 day moving average price of $3.48 and a two-hundred day moving average price of $3.69. The company has a debt-to-equity ratio of 1.71, a quick ratio of 2.51 and a current ratio of 2.62. The stock has a market capitalization of $291.29 million, a P/E ratio of -3.54 and a beta of 1.14.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. The company had revenue of $23.01 million for the quarter, compared to analysts’ expectations of $23.72 million. During the same quarter in the previous year, the company earned ($0.71) earnings per share. As a group, sell-side analysts expect that Alimera Sciences will post -0.13 EPS for the current year.

Analyst Ratings Changes

ALIM has been the topic of a number of recent research reports. StockNews.com lowered Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. HC Wainwright cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price objective on the stock. in a research note on Tuesday, June 25th. Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).